Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Piotrowska

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|August 15, 1988
[Evaluation of bacteriologic examination of the urine of children with pyelonephritis treated during the years 1985-1986]Z Morawska, A Galar, Z Piotrowska-Gede, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2003
Defective mismatch-repair in patients with multiple primary tumours including colorectal cancerK Ericson, B Halvarsson, J Nagel, et al.
Materials Science & Engineering. C, Materials for Biological Applications|November 26, 2019
Impact of temperature on the physicochemical, structural and biological features of copper-silica nanocompositesM Dulski, K Dudek, J Podwórny, et al.
Materials Science & Engineering. C, Materials for Biological Applications|July 28, 2019
Physicochemical and structural features of heat treated silver-silica nanocomposite and their impact on biological propertiesM Dulski, J Peszke, J Włodarczyk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2018
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsZ Piotrowska, D B Costa, G R Oxnard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|August 15, 1988
[Evaluation of bacteriologic examination of the urine of children with pyelonephritis treated during the years 1985-1986]Z Morawska, A Galar, Z Piotrowska-Gede, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2003
Defective mismatch-repair in patients with multiple primary tumours including colorectal cancerK Ericson, B Halvarsson, J Nagel, et al.
Materials Science & Engineering. C, Materials for Biological Applications|November 26, 2019
Impact of temperature on the physicochemical, structural and biological features of copper-silica nanocompositesM Dulski, K Dudek, J Podwórny, et al.
Materials Science & Engineering. C, Materials for Biological Applications|July 28, 2019
Physicochemical and structural features of heat treated silver-silica nanocomposite and their impact on biological propertiesM Dulski, J Peszke, J Włodarczyk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2018
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsZ Piotrowska, D B Costa, G R Oxnard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Pageof 2